-+ 0.00%
-+ 0.00%
-+ 0.00%

Deutsche Bank Maintains Buy on Sutro Biopharma, Raises Price Target to $55

Benzinga·03/25/2026 16:43:03
Listen to the news
Deutsche Bank analyst James Shin maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $51 to $55.